Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylguanine Methyltransferase Testing in Glioblastoma: When and How?

18 Apr 2007

Abstract excerpt

Controversy remains on the optimal treatment schedule of the alkylating agent temozolomide (TMZ) in malignant glioma and the value of methylguanine methyltransferase (MGMT) determination. This repair enzyme is key in reverting lethal DNA damage induced by alkylating agent chemotherapy, and in the absence of this enzyme, cells are more susceptible to TMZ. In this issue of the Journal of Clinical Oncology, Chinot...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17442986
DOI: 10.1200/jco.2006.09.7139

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylguanine Methyltransferase Testing in Glioblastoma: When and How?PMID 17442986Read ↗

MGMT Gene Silencing and Benefit from Temozolomide in GlioblastomaSemantic proximity Read ↗

No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patientsSemantic proximity Read ↗

O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter MethylationSemantic proximity Read ↗

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical TrialsSemantic proximity Read ↗

MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectivesSemantic proximity Read ↗

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft modelsSemantic proximity Read ↗

MGMT Status as a Clinical Biomarker in GlioblastomaSemantic proximity Read ↗

MGMT testing—the challenges for biomarker-based glioma treatmentSemantic proximity Read ↗

Temozolomide in the Era of Precision MedicineSemantic proximity Read ↗

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.Semantic proximity Read ↗

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapySemantic proximity Read ↗

Clinical Trial Substantiates the Predictive Value of <b> <i>O-6-Methylguanine-DNA Methyltransferase</i> </b> Promoter Methylation in Glioblastoma Patients Treated with TemozolomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.